G
GeoVax Labs, Inc. (GOVX)
NCM – Real Time Price. Currency in USD
1.32
+0.01 (0.76%)
At close: Jun 26, 2026, 4:00 PM EDT
1.28
-0.04 (-3.03%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.32
+0.01 (0.76%)
At close: Jun 26, 2026, 4:00 PM EDT
1.28
-0.04 (-3.03%)
After-hours: Jun 26, 2026, 7:59 PM EDT
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
| Name | Position |
|---|---|
| Dr. Harriet Latham Robinson Ph.D. | Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board |
| Dr. John W. Sharkey Ph.D. | Vice President of Business Development |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer |
| Dr. Mark J. Newman Ph.D. | Chief Scientific Officer |
| Mr. David Alan Dodd | Chairman, President & CEO |
| Mr. Jeffrey Welch | Head of Process Development & Manufacturing Operations |
| Mr. Mark W. Reynolds CPA | CFO & Corporate Secretary |
| Mr. Thomas O'Brien | Vice President of Quality Systems & Compliance |
| Date | Type | Document |
|---|---|---|
| 2026-06-17 | 8-K | govx20260617_8k.htm |
| 2026-05-26 | S-1 | govx20260522_s1.htm |
| 2026-05-19 | 8-K | govx20260519_8k.htm |
| 2026-05-18 | DEFR14A | govx20260512_defr14a.htm |
| 2026-05-14 | 8-K | govx20260513_8k.htm |
| 2026-05-14 | 10-Q | govx20260331_10q.htm |
| 2026-05-08 | PRER14A | govx-20251231.htm |
| 2026-05-07 | 8-K | govx20260507_8k.htm |
| 2026-04-27 | DEF 14A | govx20260421_def14a.htm |
| 2026-04-17 | POS EX | govx20260417e_posex.htm |